Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
X Jiang, W Li, X Li, H Bai, Z Zhang - … management and research, 2019 - Taylor & Francis
… single agents and in combination with chemotherapy, antiangiogenic agents, and ionizing
… inhibitors have no effect on tumor cells with the complete absence of the PARP1 enzyme. …
… inhibitors have no effect on tumor cells with the complete absence of the PARP1 enzyme. …
Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status
Y Wu, S Xu, S Cheng, J Yang, Y Wang - Journal of Ovarian Research, 2023 - Springer
… ovarian cancer is surgery combined with chemotherapy. In … , PARP inhibitors can capture
PARP1, resulting in DNA damage … to the clinical trials of PARP inhibitors on ovarian cancer, …
PARP1, resulting in DNA damage … to the clinical trials of PARP inhibitors on ovarian cancer, …
[HTML][HTML] Therapeutic applications of PARP inhibitors in ovarian cancer
H Xie, W Wang, B Xia, W Jin, G Lou - Biomedicine & Pharmacotherapy, 2020 - Elsevier
… -based chemotherapy [63]. Clinical trials of niraparib in ovarian cancer mainly concentrated
… DNA damage occurs following chemotherapy, resulting in PARP1 protein activation that …
… DNA damage occurs following chemotherapy, resulting in PARP1 protein activation that …
The molecular mechanisms of actions, effects, and clinical implications of PARP inhibitors in epithelial ovarian cancers: a systematic review
CH Lau, KM Seow, KH Chen - International Journal of Molecular Sciences, 2022 - mdpi.com
… and the results from the clinical studies that investigated the effects … Among all kinds of PARP,
PARP-1 is the most important … over chemotherapy when used in relapsed ovarian cancers. …
PARP-1 is the most important … over chemotherapy when used in relapsed ovarian cancers. …
PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective
V Loizzi, G Ranieri, M Laforgia… - Oncology …, 2020 - spandidos-publications.com
… human ovarian cancer cells transfected with PARP-1 small … of cytotoxic chemotherapy (51).
Promising data from more recent … III clinical trials testing veliparib not only in ovarian cancer, …
Promising data from more recent … III clinical trials testing veliparib not only in ovarian cancer, …
PARP inhibitor drugs in the treatment of breast, ovarian, prostate and pancreatic cancers: an update of clinical trials
D Kamel, C Gray, JS Walia, V Kumar - Current drug targets, 2018 - ingentaconnect.com
… inhibitorchemotherapy hybrid targeting HR deficient cancers … single arm phase II trial,
monotherapeutic effect of Rucaparib … breast cancer where patients had received PARP-1 inhibitor …
monotherapeutic effect of Rucaparib … breast cancer where patients had received PARP-1 inhibitor …
Treatment of ovarian cancer beyond PARP inhibition: current and future options
V Garg, AM Oza - Drugs, 2023 - Springer
… Pathways of resistance to PARPi and chemotherapy have been … due to exclusion from clinical
trials. Bevacizumab concurrently … PARP1 function can be affected due to mutations or post-…
trials. Bevacizumab concurrently … PARP1 function can be affected due to mutations or post-…
PARP inhibitors in epithelial ovarian cancer: state of art and perspectives of clinical research
A Gadducci, ME Guerrieri - Anticancer Research, 2016 - ar.iiarjournals.org
… chemotherapy and as palliative treatment of platinum-resistant disease. Germline BRCA testing
should be offered to all patients with ovarian cancer… to readily detect PARP1–and PARP2…
should be offered to all patients with ovarian cancer… to readily detect PARP1–and PARP2…
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
GE Konecny, RS Kristeleit - British journal of cancer, 2016 - nature.com
… evaluated in late-stage clinical trials of ovarian cancer (OC). … pathway components and role
of PARP1 for each pathway. (… with chemotherapeutic agents in early phase I clinical trials, …
of PARP1 for each pathway. (… with chemotherapeutic agents in early phase I clinical trials, …
Advances in the treatment of ovarian cancer using PARP inhibitors and the underlying mechanism of resistance
L Wang, Q Wang, Y Xu, M Cui, L Han - Current Drug Targets, 2020 - ingentaconnect.com
… is cytoreductive surgery followed by cytotoxic chemotherapy. … -blind, phase Ⅲ clinical trial
that assessed the efficacy of … In ovarian cancer cell lines, PARP1 expression is positively …
that assessed the efficacy of … In ovarian cancer cell lines, PARP1 expression is positively …